Medication-overuse headache: risk factors, pathophysiology and management

被引:189
作者
Diener, Hans-Christoph [1 ]
Holle, Dagny
Solbach, Kasja
Gaul, Charly
机构
[1] Univ Hosp Essen, Dept Neurol, Hufelandstr 55, D-45147 Essen, Germany
关键词
STRUCTURED DETOXIFICATION PROGRAMS; PLACEBO-CONTROLLED PHASE; GREY-MATTER CHANGES; CHRONIC MIGRAINE; DOUBLE-BLIND; WITHDRAWAL HEADACHE; ANALGESIC-OVERUSE; PSYCHIATRIC COMORBIDITY; TRANSFORMED MIGRAINE; SEROTONIN RECEPTOR;
D O I
10.1038/nrneurol.2016.124
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Medication-overuse headache (MOH) is defined by the International Classification of Headache Disorders as a headache in patients with a pre-existing primary headache disorder that occurs on = 15 days per month for > 3 months, and is caused by overuse of medication intended for acute or symptomatic headache treatment. The prevalence of MOH in the general population is around 1%, but the condition is much more common in people with headache, in particular chronic migraine. The phenotype of the headache in MOH depends on the initial primary headache and the type of overused acute medication. In this Review, we will discuss the epidemiology, risk factors, pathophysiology, prevention and treatment of MOH. Treatment of MOH is performed in three steps: educating patients about the relationship between frequent intake of acute headache medication and MOH with the aim to reduce intake of acute medication; initiation of migraine prevention (such as topiramate or onabotulinumtoxin A in migraine) in patients who fail step 1; detoxification on an outpatient basis or in a day hospital or inpatient setting, depending on severity and comorbidities. The success rate of treatment is around 50-70%, although patients whose MOH is associated with opioid overuse have higher relapse rates. In all patients with MOH, relapse rates can be reduced by patient education and care in the follow-up period.
引用
收藏
页码:575 / 583
页数:9
相关论文
共 101 条
[1]  
Andersen S, 2009, PHARMACOGENOMICS, V10, P669, DOI [10.2217/pgs.09.13, 10.2217/PGS.09.13]
[2]   Psychiatric comorbidity in medication overuse headache patients with pre-existing headache type of episodic tension-type headache [J].
Atasoy, HT ;
Atasoy, N ;
Unal, AE ;
Emre, U ;
Sumer, M .
EUROPEAN JOURNAL OF PAIN, 2005, 9 (03) :285-291
[3]  
Aurora SK, 2010, CEPHALALGIA, V30, P793, DOI 10.1177/0333102410364676
[4]   Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures [J].
Ayzenberg, I. ;
Obermann, M. ;
Nyhuis, P. ;
Gastpar, M. ;
Limmroth, V. ;
Diener, H. C. ;
Kaube, H. ;
Katsarava, Z. .
CEPHALALGIA, 2006, 26 (09) :1106-1114
[5]   The prevalence of primary headache disorders in Russia: A countrywide survey [J].
Ayzenberg, I. ;
Katsarava, Z. ;
Sborowski, A. ;
Chernysh, M. ;
Osipova, V. ;
Tabeeva, G. ;
Yakhno, N. ;
Steiner, T. J. .
CEPHALALGIA, 2012, 32 (05) :373-381
[6]   Does chronic daily headache arise de novo in association with regular use of analgesics? [J].
Bahra, A ;
Walsh, M ;
Menon, S ;
Goadsby, PJ .
HEADACHE, 2003, 43 (03) :179-190
[7]   Variant BDNF (VAl66Met) impact on brain structure and function [J].
Bath, KG ;
Lee, FS .
COGNITIVE AFFECTIVE & BEHAVIORAL NEUROSCIENCE, 2006, 6 (01) :79-85
[8]   Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project) [J].
Bendtsen, L. ;
Munksgaard, S. B. ;
Tassorelli, C. ;
Nappi, G. ;
Katsarava, Z. ;
Lainez, M. ;
Leston, J. A. ;
Fadic, R. ;
Spadafora, S. ;
Stoppini, A. ;
Jensen, R. .
CEPHALALGIA, 2014, 34 (06) :426-433
[9]   Transformed migraine and medication overuse in a tertiary headache centre - clinical characteristics and treatment outcomes [J].
Bigal, ME ;
Rapoport, AM ;
Sheftell, FD ;
Tepper, SJ ;
Lipton, RB .
CEPHALALGIA, 2004, 24 (06) :483-490
[10]   Brain-derived neurotrophic factor [J].
Binder, DK ;
Scharfman, HE .
GROWTH FACTORS, 2004, 22 (03) :123-131